Remus Pharmaceuticals Limited (NSEI: REMUS)
Health Care · Health Care Providers & Services · IN
Rs897.35
+6.54% today · -2.1% 1Y
Remus Pharmaceuticals Limited (NSEI: REMUS) operates in the Health Care Providers & Services industry within the Health Care sector. The company is valued at $109.40M and employs 68 people.
Over the last twelve months the share price has lost 2.1%, trading between 580.00 and 952.00.
Tweenvest scores Remus Pharmaceuticals Limited across four factors: quality 64/100, value 71/100, growth 100/100, dividend 2/100. Its strongest factor is growth.
REMUS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $109.40M
- Revenue (TTM)
- $91.04M
- P/E
- 22.90
- EPS
- 39.19
- Dividend yield
- 0.11%
- Beta (5Y)
- 0.24
- 52-week high
- Rs952.00
- 52-week low
- Rs580.00
- Avg volume (3M)
- —
- Shares outstanding
- 11.66M
- Employees
- 68
- Next earnings
- —
About Remus Pharmaceuticals Limited
Remus Pharmaceuticals Ltd. is a pharmaceutical company engaged in the marketing, trading, and distribution of finished dosage formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company's diverse product portfolio, exceeding 600 offerings, includes tablets, capsules, injections, creams, gels, eye drops, and various other dosage forms. Remus Pharmaceuticals focuses on therapeutic categories such as Critical Care, Oncology, Nephrology, Central Nervous System, Cardiology, Diabetics, Antibiotics, Immunosuppressants, Anti-inflammatory, Antifungal, Antipsychotic, Antiretroviral, Dermatology, Urology, and products for vitamin deficiency. The company primarily targets export markets, with significant operations in the Middle East, Africa, Southeast Asia, Latin America, and other emerging global markets. Leveraging an asset-light business model, Remus Pharmaceuticals collaborates with third-party and contract manufacturers, while also possessing manufacturing capabilities in India and the USA, to produce and distribute cost-effective generic alternatives. Additionally, the company provides technical and consultancy services for preparing product dossiers for international registration and engages in research and development for generic drugs and clinical trials.
- ISIN
- INE0O5T01011
- Founded
- 2015
- Listed since
- May 29, 2023
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Health Care Providers & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| UnitedHealth Group IncorporatedNYSE: UNH | $357.92B | $398.35 | -0.10% |
| CVS Health CorporationNYSE: CVS | $120.36B | $93.07 | -1.11% |
| McKesson CorporationNYSE: MCK | $101.88B | $896.60 | +2.61% |
| HCA Healthcare, Inc.NYSE: HCA | $92.93B | $427.92 | -0.31% |
| Elevance Health, Inc.NYSE: ELV | $87.32B | $399.83 | -0.70% |
| The Cigna GroupNYSE: CI | $74.11B | $278.24 | -0.79% |
| Cencora, Inc.NYSE: COR | $61.78B | $325.28 | +0.47% |
| Cardinal Health, Inc.NYSE: CAH | $54.04B | $235.84 | +1.49% |
Figures last refreshed Aug 18, 2026.